Zandatrigine is under clinical development by Neurocrine Biosciences and currently in Phase II for Epileptic Encephalopathy. According to GlobalData, Phase II drugs for Epileptic Encephalopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Zandatrigine LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zandatrigine overview

Zandatrigine is under development for the treatment of rare infantile epileptic encephalopathies such as SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).  It acts by targeting selective Nav1.6. The drug candidate is developed based on extreme genetics platform. It is administered through oral route and formulated as a capsule and granules dosage forms.

It was also under development for Dravet syndrome and partial seizure (focal-onset seizures).

Neurocrine Biosciences overview

Neurocrine Biosciences (Neurocrine) discovers, develops, and sells pharmaceutical products for the treatment of neurologic, neuropsychiatric, and neuroendocrine-related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule, is a US FDA-approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). The company’s major pipeline products include valbenazine in Phase III clinical trials for the treatment of chorea in Huntington’s disease and adjunctive treatment of Schizophrenia; NBI-1065846 in Phase II clinical trial for anhedonia in depression; NBI-827104 in Phase II clinical trials for rare pediatric epilepsy; NBI-921352 in Phase II trials for focal onset seizures in adults; crinecerfont (NBI-74788), a corticotropin-releasing factor1 (CRF1) antagonist in Phase III trials for congenital adrenal hyperplasia in adults and in Phase II trials for congenital adrenal hyperplasia in pediatric patients. Neurocrine is headquartered in San Diego, California, the US.

For a complete picture of Zandatrigine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.